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1. Introduction 
Parkinson’s disease (PD) is an adult-onset disease of unknown etiology, with a prevalence of 
0.3% in the entire population, affecting more than 1% of humans over 60 years of age. 
Primary degeneration occurs in pigmented dopamine-containing neurons in the pars 
compacta of the substantia nigra, with projections to the striatum and typical motor signs that 
appear with a loss of 60% of the dopaminergic neurons of the brain area. While 90-95% of 
PD cases have no known genetic basis, approximately 5-10% arises from inherited mutations 
(Farooqui & Farooqui, 2011). While the actual physiopathology of PD remains uncertain, it 
is currently suggested that the molecular mechanism of the vulnerability of dopaminergic 
neurons in the substantia nigra involves monoamine oxidase-mediated abnormal dopamine 
metabolism, hydrogen peroxide generation, and abnormal mitochondrial and proteosomal 
dysfunctions along with microglia cell activation which may be closely associated with 
neurodegenerative process. The loss of dopaminergic neurons in the substantia nigra may be 
related to resting tremor, rigidity, bradykinesia, postural instability, and gait disturbance in 
PD patients. Also associated with PD neuropathology are disrupted iron homeostasis, 
intracellular deposition of proteins in Lewy bodies, and oxidative stress and neuronal 
damage. 
PD is considered the paradigm of -synucleinopathies within the spectrum of 
neurodegenerative diseases that exhibit -synuclein in cytosolic protein aggregates 
(Navarro et al., 2009). 
There is evidence that oxidative stress participates in the neurodegeneration (Lustig et al., 
1993; Famulari et al., 1996; Repetto et al., 1999; Fiszman et al., 2003; Domínguez et al., 2008); 
neutrophils express a primary alteration of nitric oxide release in PD patients, where 
reactive oxygen species and oxidative stress parameters are more probably related to the 
evolution of PD (Gatto et al., 1996; Gatto et al., 1997; Repetto & Llesuy, 2004). Peripheral 
markers of oxidative stress in red blood cells of neurological patients could be a reflection of 
the brain condition and suggests that oxygen free radicals are partially responsible for the 
damage observed in PD living patients (Serra et al., 2001; Repetto, 2008). Other reports 
suggest that mitochondrial dysfunction and impairment of the respiratory complexes are 
associated with the neuronal loss (Boveris & Navarro, 2008). Moreover, increased mDNA 
deletions were recognized in nigral neurons in PD (Bender et al., 2006). 
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1.1 Clinical criteria diagnosis in idiopathic Parkinson’s disease 
The differential diagnosis of parkinsonian syndromes is considered one of the most 
challenging in clinical neurology. Despite published consensus operational standards for the 
diagnosis of idiopathic Parkinson's disease (PD) and the various parkinsonian disorders, 
such as secondary Parkinson's disease, progressive supranuclear palsy, multiple system 
atrophy and corticobasal degeneration, the clinical separation of PD requires the application 
of strict diagnostic criteria. 
The diagnosis of the specific secondary Parkinsonism was based on the constellation of 
clinical features suggestive of a secondary etiology (Gibb et al., 1988; Quinn, 1989; Dalakas et 
al., 2000; Schrag et al., 2002), namely: Manifestations and suspected etiologies of non PD, 
Vascular Parkinsonism, Drug-induced Parkinsonism, Multiple System Atrophy, Lewy body 
dementia, Toxin exposure (carbon-monoxide poisoning), Progressive supranuclear palsy, 
Hemiparkinsonism – hemiatrophy, Juvenile Parkinsonism with dystonia and hemiatrophy, 
Walking apraxia-ataxia frontal lobe, Action or postural tremor prominent (essential tremor) 
and the Stiff person syndrome. 
While the clinical characteristics of the Parkinson syndrome facilitate the diagnosis, which is 
easy in the advanced stages in the paucisymptomatic forms or at the early stages the 
diagnosis becomes more difficult. 
In the absence of a biological marker diagnosis in life can only be performed by clinical 
criteria. In recent decades the criteria used were not universally recognized, and the PD 
could be over diagnosed. In a study carried out between 1999 and 2000 (Serra et al., 2001) 
patients were recruited if they had, at least, two cardinal symptoms of PD according to 
clinical criteria (Hughes et al., 1992) and, additionally, Hoehn and Yahr stage 1 to 3 (Hoehn 
& Yahr, 1967), to assess the severity at presentation and progression. Patients also required a 
history of positive response to levodopa therapy. 
Currently, the diagnosis of PD follows the United Kingdom Brain Bank Criteria, which 
demands bradykinesia and one additional symptom, i.e., rigidity, resting tremor or postural 
instability. The latter is not a useful sign for the early diagnosis of PD, because it does not 
appear before Hoehn and Yahr stage 3. Other symptoms of PD which precede the onset of 
motor disturbances are hyposmia, REM sleep behavioral disorder, constipation and 
depression. The clinical diagnosis of PD can be supported by levodopa or apomorphine 
tests. Imaging studies such as cranial CT or MRI are helpful to distinguish PD from atypical 
or secondary Parkinson's disease. 
In the last decade the Unified Parkinson’s Disease Rating Scale (UPDRS) is the most widely 
used clinical rating scale for PD. Authors unanimously considered the concept of a single 
clinical rating scale to be an important tool for clear and consistent communication among 
movement disorder colleagues (Fahn et al., 1987; Movement Disorder Society Task Force, 
2003). 
1.2 Biochemical mechanisms associated to Parkinson’s disease 
The degradation processes of macromolecules, such as serotonin, norepinephrine, 
dopamine, and other neurotransmitters of dopaminergic neurons in substantia nigra, 
catalyzed by monoamine oxidase are critically important not only for the regulation of 
emotional behavior, but also for other neural functions. As a consequence, the brains of PD 
patients are subject to high levels of oxidative stress. The dopaminergic cell loss and disease 
progression are accompanied by the accumulation of high iron levels, associated with 
aggregation of -synuclein (especially in the mutated form found in familial Parkinson’s 
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disease). Increasing evidence indicates that multiple biochemical and cellular factors are 
involved in neuronal death in PD, some of them involve protein dyshomeostasis, 
mitochondrial impaired function and metal-induced toxicity. These processes contribute to 
the oxidative stress and damage and inflammatory response in brain of PD patients 
(Farooqui & Farooqui, 2011). The current views on PD consider that this disease is not only 
characterized by substantia nigra dysfunction but that it also involves the frontal cortex with 
a cognitive decline at the early stages of Parkinsonism (McNamara et al., 2007). Oxidative 
damage and mitochondrial dysfunction in the human frontal cortex are considered factors 
that lead to impaired cognition in PD patients. 
1.2.1 Protein dyshomeostasis 
The neuropathological hallmarks of PD include the presence of Lewy bodies mostly 
composed of -synuclein, a presynaptic protein that not only plays an important role in 
neuropathology of PD, but is also known to bind divalent metals as iron (Fe) and copper 
(Cu), which accelerates the aggregation of -synuclein to form various toxic aggregates in 
vitro. Although the normal biological function of this protein remains to be elucidated, it is 
clear that regulation of its expression is essential for healthy neuronal function. Even a 1.5 
fold elevation in its expression is sufficient to produce Lewy body disease (Sigletton et al., 
2003). Membrane-bound -synuclein may play a role in fibril formation. Overexpression of 
-synuclein impairs mitochondrial function and increases oxidative stress. This prion 
protein has a neuroprotective function by acting as antiapoptotic factor that inhibits the 
mitochondria-mediated apoptosis by preventing the formation of the permeability pore of 
the inner mitochondrial membrane (Opazo et al., 2003; Kozlowski et al., 2009). 
These effects are associated to mitochondrial dysfunction due to decreased activity of 
cytochrome c oxidase and to the increased production of reactive oxygen species, which in 
turn triggers mitochondria-mediated apoptotic neurodegeneration (Rossi et al., 2004; 
Spencer et al., 2009). 
1.2.2 Mitochondrial impaired function 
Neurochemically, PD is characterized by mitochondrial dysfunction and brain 
mitochondrial oxidative damage. There are also consistent observations of the impaired 
functioning of mitochondrial respiratory transport chain at the site of complex I (NADH 
CoQ10 reductase), from PD brain, particularly in the substantia nigra, with consequent 
aggregation and accumulation of -synuclein (Opazo et al., 2003; Friedlich et al., 2009) and 
in frontal cortex in PD patients (Boveris & Navarro, 2008). The inhibition of complex I 
observed in PD has an etiological impact. The question then arises as to the origin of the 
complex I-deficiency in PD. It could result from an environmental toxin or an acquired or 
inherited mtDNA mutation(s) (Petrozzi et al., 2007). 
The molecular mechanism involved in the inactivation of complex I is likely accounted by 
the sum of peroxinitrite mediated reactions, reactions with free radical intermediates of the 
lipid peroxidation process and amine-aldehyde adduction reactions. The inhibitory effects 
on complex I  lead synergistically to denaturation of the protein structure and to further 
increases of superoxide anion (O2-) y peroxinitrite production at the vicinity of complex I 
(Navarro et al., 2009; Navarro & Boveris, 2009). 
Inhibition of complex I creates an environment of oxidative stress that ultimately leads to 
the aggregation of -synuclein with the consequent neuronal death. Complex I dysfunction, 
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also called “complex I syndrome” results in complex I inactivation, reduced oxygen (O2) 
uptake and ATP formation, increased O2- formation, oxidative stress and lipid peroxidation, 
events that lead to neuronal depolarization and contribute to excitotoxic neuronal injury 
(Opazo et al., 2003; Kozlowski et al., 2009; Navarro & Boveris, 2009). Mitochondrial 
dysfunction in the human frontal cortex is to be considered a factor contributing to impaired 
cognition in PD in comparison to age-matched healthy controls. The mitochondrial 
impairment observed in frontal cortex in PD patients is properly described as a reduced 
frontal cortex respiration, with marked decrease in complex I activity, associated with 
oxidative damage, the latter determined by the increased content of phospholipids and 
protein oxidation products (Navarro et al., 2009). 
Deficient complex I function would likely increase production of superoxide anion by 
impairing electron flow from NADH to ubiquinone, promoting oxidative stress through 
subsequent superoxide dismutase and Fenton chemistry. Similar deficits in respiratory 
transport chain complex I have also been reported in peripheral cells (myocytes and 
platelets). 
Mitochondrial metabolic abnormalities, DNA mutations and oxidative stress contribute to 
ageing, the greatest risk factor for neurodegenerative diseases. Somatic mitochondrial DNA 
mutations have been reported in PD brain. These findings are important because the 
mitochondrial DNA encodes components of the respiratory transport chain complexes, and 
such mutations may impair efficient electron flow from NADH to molecular oxygen 
(Friedlich et al., 2009). Further, mitochondrial abnormalities occur early in most of the 
neurodegenerative disorders, and the evidence of specific interactions of disease-related 
proteins with mitochondria represents ultimate proof of mitochondrial involvement in 
neurodegeneration. 
Mitochondria are targets of metal toxicity, and in many cases a close link between metal-
induced oxidative stress, and damage and mitochondrial dysfunction has been established 
(Navarro & Boveris, 2004, Navarro & Boveris, 2009; Navarro et al., 2009, Navarro et al., 
2010). 
1.2.3 Transition metals toxicity 
Increasing evidence indicates that metal-induced toxicity is associated with the etiology of 
neurodegenerative diseases. Two main mechanisms are currently considered likely to be the 
mechanism for redox active metals: a Haber-Weiss reaction and a depletion of major 
sulfhydryls, reduced glutathione and protein –SH groups (Repetto & Boveris, 2011). 
The cellular and tisular levels of transition metals are apparently determined by regulatory 
proteins and metallochaperons that control metal capture, transport and storage. The major 
consequences of metal dyshomeostasis are mitochondrial dysfunction, oxidative stress and 
mitochondrial genomic damage which enhanced activation of the apoptotic machinery 
(Kozlowski et al., 2009). 
Transition metals including iron (Fe) mediated oxidative damage to cellular components 
through the one-electron transfer called the Fenton reaction (Fe2+ + H2O2         Fe3+ + OH. + 
OH-), which leads to production of the unstable hydroxyl radical (OH.) that will oxidize 
nucleic acid, protein, carbohydrate and lipid, whichever is proximate (Halliwell & 
Gutteridge, 1984). Disrupted iron metabolism is implicated in PD, iron levels are increased 
in the PD substantia nigra, associated with -synuclein pathology, substantial iron deposits 
are associated with neuronal loss, gliosis and Lewy body pathology. Iron sequestered in 
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Lewy bodies and other pathobiologic pools of iron in PD brains has the potential to promote 
Fenton chemistry and oxidative damage to macromolecules. Evidence of oxidative damage 
to macromolecules is abundant in post-mortem PD tissue, with proteins, nucleic acids, lipids 
and sugars, all showing evidence of oxidative modification. 
The mitochondria of Fe-treated rats show lower respiratory control in association with 
higher resting (state 4) respiration. This mitochondrial uncoupling elicited by Fe-treatment 
does not affect the phosphorylation efficiency or the ATP levels, indicating a mild degree of 
uncoupling in Fe overload (Pardo Andreau et al., 2009). 
The Fe accumulation in substantia nigra (with up to 255% increases) results in oxidative 
stress; oxidative damage, decreased reduced glutathione levels and increased dopamine 
neuronal toxicity (Kozlowski et al., 2009). The Fe-induced oxidative damage to mitochondria 
contributes to the cellular death mechanisms, arising from a diminished respiratory chain 
activity and ATP production. The significant reduction in transferrin levels, observed in 
patients with Parkinson’s diseases, is a factor contributing to increase Fe concentrations 
(Kozlowski et al., 2009; Spencer et al., 2011). 
Fe and Cu are prevalent in human tissues, including the brain, and altered levels of these 
essential metals have been found in brain tissues of patients with neurodegenerative 
diseases (Repetto & Boveris, 2011). Because approximately 20% of the total Cu is stored in 
the nucleus, DNA is the major target for copper-catalyzed oxidations. Accumulation of 
oxidative DNA base modifications, produced by dopamine and other catecholamine 
neurotransmitters and neurotoxins, is associated with elevated copper (Cu) levels in the 
presence of O2- and H2O2 and potentially results from one-electron oxidation and/or the 
site-attack of hydroxyl radicals via a DNA-Cu(I)OOH complex. Because accumulation of 
oxidative DNA has been reported as a major contributing factor to genomic instability and 
mitochondrial dysfunction in aging and neurodegenerative disorders as Alzheimer and PD, 
it probably contributes to neuronal death associated with these degenerative processes 
(Spencer et al., 2011). 
1.2.4 Oxidative stress and oxidative damage 
The concept of oxidative stress is defined as an imbalance with increased oxidants or 
decreased antioxidants (Sies, 1991). As an imbalance situation, it implies that in the normal 
physiological condition there is a balance, or a controlled situation of quasi-equilibrium 
between oxidants and antioxidants. Oxidants are continually produced as secondary 
products of respiration and oxidative metabolism and antioxidants are continually reacting 
with oxidant molecules. In the oxidative stress condition, oxidants increase or antioxidants 
decrease in a progressive and continuous form, sometimes including adaptive responses 
that involve the synthesis of antioxidants and antioxidant enzymes and that confer elasticity 
and reversibility to the biological situation of oxidative stress (Boveris et al., 2008). They 
defined the intracellular oxidative stress as a situation where increases of the steady-state 
concentrations of any intermediate produces an increase in oxidant intermediates, an 
increase in the chain reaction rate and a decrease in intracellular antioxidants. 
The brain is particularly susceptible to oxidative stress due to its high-energy demand and 
the specialized redox activities of neurons. Although the brain only constitutes 2 to 3% of 
total body mass, it utilizes 20% of basal oxygen supplied to the body. Low level of oxidants 
are needed for normal cellular functions, including, but not restricted to the regulation of 
neuronal excitability via redox-sensitive ion channels, synaptic plasticity, gene transcription, 
and the activity of enzymes controlling protein phosphorylation. At higher concentrations, 
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oxidants cause neuronal membrane damage. The biological targets of oxidants include 
membrane proteins, unsaturated lipids and DNA. 
Oxidative stress promotes aggregation and accumulation of -synuclein, characteristic of 
Parkinson’s disease (Kozlowski et al., 2009; Opazo et al., 2003). The series of observed 
changes include glycation protein oxidation, lipid peroxidation, depletion of antioxidants 
and nucleic acid oxidation (Famulari et al., 1996; Gatto et al., 1996; Gatto et al., 1997; Repetto 
et al., 1999; Fiszman et al., 2003; Boveris et al., 2008; Repetto, 2008). It has been proposed that 
oxidative damage favors the aggregation of -synuclein in sporadic PD. 
According to a now classical definition, antioxidants are molecules which, when present in 
small concentrations compared to the biomolecules that are supposed to protect, can 
prevent or reduce the extent of oxidative destruction of biomolecules. They can prevent 
initiation or intercept the lipid peroxyl radical involved in the propagation phase. In human 
plasma there are transition metal binding proteins in order to prevent metal catalysis; on the 
other side, cell membranes and lipoproteins contain lipophilic antioxidants, which are able 
to react with lipid peroxyl radicals, eventually terminating the chain reaction of lipid 
peroxidation. The implication of free radicals in various pathological processes has been 
detected in an increasing number of human diseases. The assay of oxidative stress 
parameters has brought substantial insights into the pathogenesis of many diseases in 
humans, by demonstrating the involvement of free radicals and/or the decrease of 
antioxidants. 
1.2.5 Lipid peroxidation 
Lipid peroxidation is a chain reaction initiated by the hydrogen substraction or addition of 
an oxygen radical, resulting in the oxidative damage of polyunsaturated fatty acids (PUFA). 
Since polyunsaturated fatty acids are more sensitive than saturated ones, it is obvious that 
the activated methylene (RH) bridge represents a critical target site. Molecular oxygen 
rapidly adds to the carbon-centered radical (R.) formed in this process, yielding to lipid 
peroxyl radical (ROO.). The formation of peroxyl radicals leads to the production of organic 
hydroperoxides, which, in turn, can subtract hydrogen from another PUFA. This reaction is 
termed propagation, implying that one initiating hit can result in the conversion of 
numerous PUFA to lipid hydroperoxides. In sequence of their appearance, alkyl, peroxyl 
and alkoxyl radicals are involved. The resulting fatty acid radical is stabilized by 
rearrangement into a conjugated diene that retains the more stable products including 
hydroperoxides, alcohols, aldehydes and alkanes. Lipid hydroperoxide (ROOH) is the first, 
comparatively stable, product of the lipid peroxidation reaction. In conditions in which lipid 
peroxidation is continuously initiated it gives non-radical products (PNR), destroying two 
radicals at a time. In the presence of transition metal ions, ROOH can give rise to the 
generation of radicals capable of re-initiating lipid peroxidation by redox-cycling of these 
metal ions (Halliwell & Gutteridge, 1984). 
Lipid peroxidation can have significant downstream effects and possibly play a major role 
in cell signaling pathways. For example, the mitochondrion lipid cardiolipin makes up to 
18% of the total phospholipids and 90% of the fatty acyl chains are unsaturated. Oxidation 
of cardiolipin may be one of the critical factors initiating apoptosis by liberating cytochrome 
c from the mitochondrial inner membrane and facilitating permeabilization of the outer 
membrane. The release of cytochrome c activates a proteolytic cascade that culminates in 
apoptotic cell death (Navarro & Boveris, 2009). 
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Many of these products can be found in biological fluids, as well as addition-derivatives of 
these very reactive end-products. As a result of lipid peroxidation a great variety of 
aldehydes can be produced, including hexanal, malondialdehyde (MDA) and 5-
hydroxynonenal (Repetto, 2008). Oxidation of an endogenous antioxidant reflects an 
oxidative stress that is evaluated by measuring the decrease in the total level of the 
antioxidant or the increase in the oxidative form. The only way not to be influenced by 
nutritional status is to measure the ratio between oxidized and reduced antioxidants present 
in blood. The published literature provides compelling evidence that MDA represents a side 
product of enzymatic PUFA-oxygenation and a secondary end product of non enzymatic 
(autoxidative) fatty peroxide formation and decomposition. Conceptually, these two facts 
indicate that MDA is an excellent index of lipid peroxidation. With biological materials, it 
appears prudent to consider the TBARS test more than an empirical indicator of the 
potential occurrence of peroxidative lipid damage and not as a measure of lipid 
peroxidation (Repetto, 2008). 
1.2.6 Inflammation 
Among neural cells, neurons are particularly vulnerable to oxidative damage, not only as a 
consequence of mitochondrial dysfunction (Boveris & Navarro, 2008), but also due to 
inactivation of glutamine synthetase, which reduces the uptake of glutamate by glial cells 
and increases glutamate availability at the synapse producing excitotoxicity. Oxidative 
damage to lipids and protein of neuronal membrane affects activities of membrane-bound 
enzymes, ion channels and receptors. Glial cell´s response to oxidative stress-mediated 
neurodegenerative process is extremely complex. Astrocytes may play a dual function, 
either protecting neurons from excitotoxicity through glutamate uptake system, or 
contributing to the extracellular glutamate via reversed glutamate transporter. They may 
contribute to the inflammatory response by transforming themselves into activated 
microglia and also release matrix metalloproteinase’s, oxidants, prostaglandin E2 and 
proinflammatory cytokines such as TNF-  and IL-1 (Farooqui & Farooqui, 2011). In 
addition, at the site of neurodegenerative process, neural and non-neural cells express and 
secrete cytokines, chemokine and complement proteins, which also play important roles in 
induction, propagation and maintenance of inflammatory response. Cytokines are major 
effectors of the inflammatory response; they produce their effects by interacting with 
specific membrane associated receptors. Although physiological levels of cytokines are 
necessary for normal neuronal function and survival, the increased secretion of cytokines 
during neurodegenerative process may be detrimental to neurons. 
Nitric oxide (NO) is a free radical and potent biological effectors regulating blood vessel 
dilatation and immune function and serve as a neuronal messenger in the nervous system. 
Most of the effects of NO are mediated by glutamate, although in high concentrations, may 
act as a neurotoxin. NO can react with superoxide anion to produce peroxinitrite, an even 
more potent oxidant associated with lipid peroxidation and cytotoxic effects, in part through 
the oxidizing of tissue sulfhydrils. Metabolic alterations in circulating blood cells are widely 
accepted as representative of similar central nervous system changes in human PD. 
Increased NO release of neutrophils and decreased catalase activity in erythrocytes were 
observed at the beginning of PD; H2O2 release by neutrophils and mitochondrial impaired 
function may be later signs in PD (Gatto et al., 1996). 
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1.3 Clinical evidence of oxidative stress and damage in Parkinson’s disease 
Human neurodegenerative diseases are characterized by cumulative neuronal damage that 
leads to neurological deficits when neuronal loss reaches a critical level. Actually, the clinical 
evolution of patients with neurological diseases is based on psychological tests. The current 
hypotheses are that brain oxidative stress and damage are involved in the pathogenesis of 
neurodegenerative diseases such as Alzheimer’s and Parkinson’s diseases and non-
neurodegenerative vascular dementia. Involvement of oxidative stress in the pathogenesis of 
PD is supported both, by postmortem studies and by studies showing the increased level of 
oxidative stress in the substantia nigra pars compacta (Boveris & Navarro, 2008). Under normal 
conditions, the continuous generation of oxidants is compensated by the powerful action of 
protective enzymes: superoxide dismutase (SOD), catalase and glutathione peroxidase. 
Oxidative stress may be a consequence of reduced efficiency of these endogenous antioxidants 
that may render PD patients more susceptible to oxidative stress. Increases of pro-oxidants, as 
H2O2 and nitric oxide (NO), and decreases of antioxidants, either enzymatic or non enzymatic 
compounds, are considered an indication of oxidative stress. Oxidative damage is 
characterized by increases in the levels of the oxidation products of macromolecules, such as 
thiobarbituric acid reactive substances (TBARS), and protein carbonyls. 
Oxidative stress, to which neurons are highly susceptible, is also known to induce oxidative 
changes in human red blood cells (RBCs), in vivo and in vitro (Gatto et al., 1996; Repetto & 
Llesuy, 2004, Repetto, 2008). Based on the hypothesis that oxidative changes are not organ 
specific, their activities may be evaluated in peripheral and red blood cells. 
The situation of oxidative stress evaluated by the peripheral markers of oxidative stress in 
the blood of neurological patients, seem to provide a reflection of the brain condition. Brain 
oxidative stress, with oxygen free radicals being responsible for brain damage, signals to 
peripheral blood, at least, through the diffusible products of lipid peroxidation. The 
peripheral markers provide a useful tool to determine the evolution of brain oxidative stress 
in neurological patients (Repetto, 2008). 
2. Materials and methods 
2.1 Patients 
The clinic diagnostic of PD is realized in accordance with the “United Kingdom Parkinson 
Disease Brain Bank Criteria”. Patients (n = 15, age = 66  4 years) were evaluated according 
to the Hoehn and Yahr’s scale in stages 1 to 3, and required a history of positive response to 
levodopa therapy. No patient presented vascular lesions on CT scanning. The controls 
groups (Table 1 and Table 2) consisted of 75 and 80 healthy people of 58  2 years and 71  
10 years, respectively. 
2.2 Peripheral markers of oxidative stress 
Blood was obtained by venipuncture and placed into glass tubes with heparinised syringes 
for separation of erythrocytes or mononuclear cells. 
To determine tert-butyl hydroperoxide-initiated chemiluminescence (BOOH-CL), 
heparinised blood samples were centrifuged at 300 g for 10 min. The plasma fraction 
(supernatant) was separated for evaluation of the total reactive antioxidant potential 
(TRAP). Mononuclear cells were discarded by aspiration. Erythrocytes were suspended in 
saline solution 0.9 % P/V NaCl and were washed three times by centrifugation at 300 g with 
the same saline solution at 25 ºC, and then diluted 1/10 in 1 mM acetic acid and 4 mM 
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magnesium sulfate. The protein concentration was determines with the Folin reagent, using 
bovine serum albumin (grade III) as the standard. 
The peripheral markers of oxidative stress assayed were: 
2.2.1 Tert-butyl hydroperoxide initiated chemiluminescence (BOOH-CL) 
The increased values of BOOH-CL indicate the occurrence of oxidative stress in the 
membrane of the erythrocytes due to consume of the endogenous antioxidants. The 
chemiluminescence associated to lipid peroxidation (BOOH-CL) was measured with a 
Packard Tricarb model 3355 liquid scintillation counter in the out-of-coincidence mode. This 
assay estimates indirectly and with high sensitivity the tissue levels of α-tocopherol by 
inhibition of the propagation step of lipid peroxidation, as discussed by González Flecha et 
al. (1991). Red blood cells were suspended in 4 mL of 120 mM KCl, 30 mM phosphate buffer, 
pH 7.40 at 0.1-0.2 mg protein/mL. Low-potassium glass vials of 25 mm diameter and 50 mm 
height filled with the sample suspension were used. Instrument background, in the absence 
of vials, was 2400  60 counts per minutes (cpm) and the emission from the empty vials was 
3000  60 cpm. Chemiluminescence measurements were started by the addition of 3 mM 
tert-butyl hydroperoxide and the counting continued until a maximal level of emission was 
reached, usually after 20 minutes. Determinations were carried out at 30C. The results are 
expressed as cpm/mg protein (González Flecha et al., 1991). 
2.2.2 Plasma antioxidant capacity (TRAP) 
The decreased values of TRAP in plasma indicate a reduction in the level of plasmatic 
hydrosoluble antioxidants (i.e., GSH, uric acid, ascorbic acid and bilirubin). The total 
reactive antioxidant potential of plasma was measured by chemiluminescence. This assay 
determines total endogenous water soluble antioxidants, mainly glutathione, ascorbic acid, 
bilirubin and albumin uric acid in plasma. The addition of 10 L of sample to 20 mM 2,2- 
azobis (2- amidinopropane) (ABAP) in 100 mM phosphate buffer, pH 7.40 and 40 µM 
luminol decreased the chemiluminescence to basal levels and prevented the spike of light 
emission for a period proportional to the amount of antioxidants present in the sample 
(induction time, ). The system was calibrated with Trolox (a hydrosoluble vitamin E 
analogue). The results are expressed as µmoL Trolox per g of organ, or µM Trolox 
considering 1 g of tissue as 1 mL of water (Lissi et al., 1992). 
2.2.3 Thiobarbituric acid reactive substances (TBARS) 
The increase in TBARS results from augmented levels of systemic and neuronal 
hydroperoxides that lead to an increment in lipid peroxidation. TBARS was assayed by the 
spectrophotometric determination as described by Fraga et al. (1988). Thiobarbituric acid 
reacts with malondialdehyde, a product of lipid peroxidation, showing maximal absorbance 
at 535 nm. The reaction mixture consists of 1 mL of plasma, 1 mL of 120 mM KCl, 1 mL of 30 
mM phosphate buffer, pH 7.40, 0.05 mL of buthylhydroxytoluene 4 % w/v in ethanol, 1 ml 
of thrichloroacetic acid 20 % w/v and 1 mL thiobarbituric acid 0.7 % w/v. The 
deproteinized mixture was heated at 100 C for 20 minutes. Results (E = 156 mM–1cm–1) are 
expressed as nmol/L plasma (Fraga et al., 1988). 
2.2.4 Cu–Zn superoxide dismutase (SOD) 
An increase in the activity of the antioxidant enzyme SOD has been regarded as a marker of 
systemic oxidative stress, since the up-regulation of the antioxidant enzyme expression was 
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considered as an adaptive response to the oxidative stress situation. SOD activity was 
determined by measuring the ability of red blood cells to inhibit the autoxidation of 
epinephrine at pH 10.2. The increase in absorbance at 480 nm was 0.025 U-min with no 
added SOD, and 50% inhibition was achieved by 46 ng/mL of bovine SOD. One unit of SOD 
activity was defined as the inhibition of the epinephrine oxidation rate by 50%. The 
inhibition was determined comparing the regression lines of autoxidation of epinephrine 
standard solutions against varying amounts of sample. Activity is expressed in U SOD/mg 
protein (Misra & Fridovich, 1972; Serra et al., 2000). 
3. Results 
The data given in Table 1 show the association of PD with oxidative stress. BOOH-CL was 
increased by 86% and TRAP values showed a decrease of 33% in PD, together with increases 
of 19% in TBARS and 55% in SOD, by comparison with the healthy controls (Serra et al., 














202  10 
p < 0.001 
n = 12 
242  25 
p < 0.001 
n = 12 
3.46 ± 0.18 
p < 0.05 
n = 15 
15.83 ± 0.57 
p < 0.001 
n = 15 
Table 1. BOOH-CL and TRAP in erythrocytes and plasma of patients with Parkinson’s 
disease; TBARS in plasma and SOD in erythrocytes. Probabilities as compared against 
pooled healthy controls (n = 75) of comparable ages. 
The concentration of non-enzymatic antioxidants decreases during oxidative damage. A 
lower level of antioxidants as a consequence of a previous situation of oxidative damage 
will correspond to a higher BOOH-CL, TBARS and SOD. These three increases are 
indicative of the occurrence of systemic oxidative stress. 
Present results demonstrate that the BOOH-CL, TBARS, TRAP and SOD variables for 
determining oxidative stress and antioxidant status would be a useful tool for the 
biochemical and clinical evaluation of patients during the progression of the disease and 
clinical treatment (Repetto, 2008; Serra et al., 2009). 
Chemiluminescence methods allow evaluating and quantifying the toxic oxygen species and 
antioxidant defenses in blood samples of the patients. They are: tert-butyl hydroperoxide 
initiated chemiluminescence (BOOH-CL) and total reactive antioxidant potential (TRAP). 
Chemiluminescence occurs when a chemical reaction produces an electronically excited 
species which emits light on its return to the ground state. Singlet oxygen and triplet 
carbonyl compounds are the most important chemiluminescent species in lipid peroxidation 
of biological systems (Figure 1). 
The experimental conditions defined here for BOOH-CL (Figure 1) and TRAP (Figure 2) 
may be used to evaluate oxidative stress in blood of patients in PD patients. The two assays 
appear as useful to evaluate the overall level of the non-enzymatic antioxidant defenses in 
the sample. The substances that constitute the non-enzymatic antioxidant defenses (-
tocopherol, ascorbic acid, retinal, uric acid, albumin, ceruloplasmin, glutathione, etc) 
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decrease their concentration during oxidative stress due to their reaction with reactive 
oxygen or nitrogen species and, in consequence, their elimination. 
The levels of methaemoglobin (Met-Hb) are regarded as an index of intracellular damage to 
the red cell, increased when -tocopherol is consumed and the rate of lipid peroxidation is 
increased. Scavenging of free radicals by -tocopherol is the first and the most critical step in 
defending against oxidative damage to the red cells. When -tocopherol is adequate, GSH 
and ascorbic acid may complement the antioxidant functions of -tocopherol by providing 
the reducing equivalents necessary for its recycling/regeneration. 
On the other hand, when -tocopherol is absent, GSH and ascorbic acid may release 
transitional metals from the bound forms and/or maintain metal ions in a catalytic state. 
Free radical generation catalyzed by transition metal ions can in turn initiate oxidative 
damage to cell membranes. Membrane damage leads to the release of heme compounds of 
the erythrocytes. The heme compounds released may further promote oxidative damage 
especially when reducing compounds are present. 
The lower level of antioxidants as a consequence of the occurrence of oxidative stress is also 
sustained by higher values of chemiluminescence (Figures 1 and 2). The increase of BOOH-
CL is indicative that -tocopherol is the antioxidant consumed in erythrocytes and suggest 
that reactive oxygen species and lipid peroxidation catalyzed by reduced transition metals 
may be responsible for the onset of oxidative damage and the occurrence of systemic 
oxidative stress in patients suffering PD (Table 1). 
 
 
Fig. 1. Photoemission kinetics of chemiluminescence (BOOH-CL) in erythrocytes of a control 
subject and a PD patient. 
The evolution of chemiluminescence shows that at 30 min of the beginning of the lipid 
peroxidation propagation step, the erythrocyte’s BOOH-CL of PD patients were 3 fold 
greater than those observed in the control subject (control value: 100 x 102 cpm) (Figure 1). 
These results are in agreement with the consumption time of the endogenous hydrosoluble 
antioxidants in plasma, showing a 50% of decrease in the induction time in PD patients 
compared with control subject (control value: 4 min) (Figure 2). 
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As cell membranes and lipoproteins contain lipophilic antioxidants and plasma contains 
hydrophilic antioxidants, that are able to react with lipid peroxyl radicals, eventually 
terminating the chain reaction the chemiluminescence technique may be applied to study 
the antioxidant effect of many compounds or the presence of antioxidant molecules in a 
biological tissue. The reaction between a lipid and hydroperoxyl radicals with a molecule of 
antioxidant prevent the emission of light (González Flecha et al., 1991; Repetto, 2008). 
 
 
Fig. 2. Time profiles of luminol luminescence with plasma from a PD patient and a control 
subject. 
The biological effects induced by free radicals are neutralized in vivo by antioxidative 
defense mechanisms, which include ascorbic acid, uric acid, -tocopherol, carotenoids, 
glutathione and antioxidant enzymes. However, the extensive generation of oxygen reactive 
species in some pathological conditions appears to overwhelm natural defense mechanisms, 
thereby reducing dramatically the levels of endogenous antioxidants. 
The non-enzymatic antioxidants decrease their concentration during oxidative damage. A 
lower level of antioxidants as a consequence of a previous situation of oxidative damage 
will correspond to a higher chemiluminescence. The increase of BOOH-CL is indicative of 
the occurrence of systemic oxidative stress. 
Accordingly, there is a statistically significant decrease in the measured TRAP, suggesting 
that an enhanced susceptibility of erythrocytes to the oxidative stress correlates with a 
decrease in its antioxidant defenses (Figures 3 and 4). 
Chemiluminescence is a simple method to providing tools to evaluate the clinical situation 
of patients, allowing quantification of the plasma antioxidant content, the correlation with 
the advance of the pathology, the effects of pharmacological treatments and the relative 
contribution of total endogenous antioxidants to the plasma. 
Chemiluminescence is a collective term, which includes the emission of light by molecules 
which have been excited to a higher energy level as a result of a chemical reaction. Singlet 
oxygen or triplet carbonyl compounds are likely to be the most important chemiluminescent 
species in lipid peroxidation of biological systems; both of them can originate from 
recombination of two peroxyl radicals to a non-radical product according to Russell’s 
mechanism by a number of chemical pathways. 
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Fig. 3. Correlation between BOOH-CL in erythrocytes and TRAP in plasma of PD patients. 
Pearson’s correlation coefficient was 0.790 (p < 0.001). The solid line is the linear regression 
(r = -0.752), dotted lines the 99% confidence intervals. 
Although lipids in the cell are protected from autoxidation by a protein coat and/or by the 
presence of high concentration of antioxidants, it seems evident that some autoxidation of 
PUFA in cells must occur. Antioxidant status in biological samples is regarded as an 
indicator of oxidative stress, and in many cases low antioxidant capacity of tissue and body 
fluids is a consequence of increased oxidative processes (Halliwell & Gutteridge, 1984). 
 
 
Fig. 4. Correlation between BOOH-CL in erythrocytes and TRAP in plasma of control group. 
Pearson’s correlation coefficient was 0.600 (p < 0.01). The solid line is the linear regression (r 
= -0.554), dotted lines the 99% confidence intervals. 
Close quantitative correspondences were found when TRAP and BOOH-CL were plotted 
against the Hoehn and Yahr’s scale in Parkinson’s patients (Figures 5 and 6). 
The evidence linking neurodegenerative diseases with oxidative stress suggested that 








Fig. 5. Correlation between erythrocyte BOOH-CL and Hoehn and Yahr’s clinical scale of 
PD patients (Pearson’s correlation coefficient, r = 0.842, p < 0.001). The solid line is the linear 
regression (r = 0.857), dotted lines the 99% confidence intervals. 
This hypothesis was tested using Discriminant Analysis in order to find if it is possible to 
separate PD, Alzheimer’s disease patients (AD), Vascular dementia patients (VD) and 
healthy controls (C)  based on the measured biochemical variables (Serra et al., 2001). 
The first Discriminant Function (DF) obtained was: DF 1 = - 18.47 SOD - 1.21 CAT - 0.99 GSH - 
3.42 TBARS + 2.42 TRAP - 1.12 Age + 30.23, where CAT and GSH are the values of the 
antioxidant enzyme catalase and the glutathione system respectively which, albeit not yielding 
significant differences per se, proved useful when included in the discriminant function. 
The values assigned by this function to each observation resulted in the correct identification 
of 100% of PD, 94% of AD and 100% of VD as diseased subjects and 93% of the C group as 
healthy. It was also possible to discriminate between DAT and VD using the second DF: 
DF 2 = - 1.16 SOD + 0.86 CAT + 1.34 GSH + 2.26 TBARS - 1.35 TRAP + 3.58 Age - 5.59, which 
correctly identified 88.9% of DAT and 73.3% of VD. 
 
 
Fig. 6. Correlation between TRAP and Hoehn and Yahr’s clinical scale of PD (Pearson’s 
correlation coefficient, r = 0.890, p < 0.003). Solid line is the linear regression (r = -0.684), 
dotted lines the 99% confidence intervals. 
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The discriminant functions define four quadrants (Figure 7) with the healthy controls lying 
in the negative X (first Discriminant Function) region and all the diseased subjects in the 
positive X. The AD patients fall in the positive X and positive Y (second Discriminant 
Function) and the VD in the positive X and negative Y. The PD patients were not associated 
with any of the other groups of patients (9 were classified as AD and 6 as VD). 
 
 
Fig. 7. Plot of pathological and control subjects on the two axes derived from Discriminant 
Functions. Clinical conditions are: PD patients (n = 15): Filled circles; AD Patients (n = 18): 
Empty triangles; VD Patients (n = 15): Empty squares; Healthy Controls (n = 14): Asterisks. 
The Discriminant Function 2 correctly recognizes AD and VD, showing that these two 
groups might be considered as separate oxidative disorders (measured by biochemical 
variables of the peripheral oxidant/antioxidant system). The control and diseased regions 
are clearly separated, as well as AD and VD regions. PD patients are evenly distributed 
overlapping AD and VD, suggesting biochemical similarities with both diseases. 
The peripheral antioxidant profile of PD shows a degree of overlap (already shown in 
Figure 7) with those of AD and VD. While dementias can be readily distinguished from each 
other, the PD profile might be described as intermediate between AD and VD. This might be 
explained noting that the main neuronal populations affected are different in each disease. 
Their identity (dopaminergic, noradrenergic, serotoninergic and cholinergic) is well 
established: mainly dopaminergic neurons die in PD and cholinergic neurons in AD 
patients; while VD doesn’t present neuronal selectivity. The three diseases are associated 
with oxidative disorders predominating in different anatomical areas of the brain. An 
intermediate mechanism might be hypothesized for the PD patients (Serra et al., 2001). 
Table 2 presents the values of the oxidant and antioxidant variables in the three 
neurological diseases and healthy controls studied obtained in a different protocol (Serra 
et al., 2009). 
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n = 15 
3.46 ± 0.18 
p < 0.05 
295 ± 26 
p < 0.01 
15.83 ± 0.57 
p < 0.001 
49.5 ± 3.4
N.S. 




n = 112 
3.61 ± 0.13 
p < 0.001 
277 ± 12 
p < 0.001 
17.75 ± 0.47 
p < 0.001 
43.9 ± 3.0
N.S. 




n = 57 
3.50 ± 0.12 
p < 0.01 
309 ± 18 
p < 0.001 
16.69 ± 0.61 
p < 0.001 
39.4 ± 3.8
N.S. 




n = 80 
2.91 ± 0.08 410 ± 19 10.24 ± 0.28 45.8 ± 3.9 1.9 ± 0.2 
Table 2. TBARS, TRAP measured in plasma, the enzymes SOD, CAT and GPx (glutathione 
peroxidase) measured in erythrocytes of patients with Parkinson’s disease, Alzheimer’s 
disease and Vascular dementia. Probabilities as compared against pooled healthy controls of 
comparable ages. RBC: Red blood cells; N.S.: non-significant differences. 
As free radical stress results from an imbalance between free radical production and 
antioxidant system, it may be possible to measure the antioxidant levels separately or as a 
total global antioxidant capacity of a biological tissue. The reactive oxygen and nitrogen 
species are generated in living systems and oxidize a number of cellular constituents like 
lipids, proteins and DNA. As a consequence of this, antioxidants come into play and act as 
free radical scavengers, inhibit lipid peroxidation and other free radical mediated processes; 
they are able to protect the human body from several diseases attributed to the reaction of 
radicals. 
Moreover, the present results show linearity between pairs of oxidative stress variables and 
the ordering of the neurological patients’ diseases along the different regression lines 
pointing to the existence of an overall balance between oxidative insult, damage and 
protection (Table 2 and Figures 8 and 9) (Serra et al., 2009). 
The linear correlations described between the three variables also include a significant 
negative linear correlation between plasma TRAP and erythrocyte SOD (r = -0.980, p < 0.001, 
not shown), which is implied by the other two relationships. 
4. Conclusions 
PD is a common neurodegenerative movement disorder, which affects increasing numbers 
of the elderly population. The disorder is characterized by a selective degeneration of 
dopaminergic neurons in the substantia nigra. Although the molecular mechanism associated 
with neurodegeneration in PD is not known, it is becoming increasingly evident that 
neuronal death in this disease is a multifactorial process that may involve monoamino 
oxidase-mediated abnormal dopamine metabolism, increase of iron levels, hydrogen peroxide 
generation, transition metal and -synuclein dyshomeostasis, abnormal mitochondrial 
function and oxidative stress and damage. Free radicals have been postulated as involved 
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Fig. 8. Correlation between plasma TBARS and plasma TRAP values. Mean values (points) 
and standard error (bars), solid line is the linear regression (r = -0.989), dotted lines the 99% 
confidence intervals. C: healthy controls (n = 80); PD: Parkinson’s disease patients (n = 15); 
AD: Alzheimer’s disease patients (n = 112); VD: Vascular Dementia patients (n = 57) (Data 
from Serra et al., 2009). 
 
 
Fig. 9. Correlation between plasma TBARS and erythrocyte SOD values (r = 0.998). Statistics 
and abbreviations as in Figure 8 (Serra et al., 2009). 
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in PD disease. The concept of free radical involvement is supported by enhanced basal lipid 
peroxidation in substantia nigra (Navarro & Boveris, 2009) and plasma of PD patients, 
demonstrated by increased levels of TBARS and lipid peroxidation. The assay of oxidative 
stress parameters in plasma and red blood cells in humans is usually attempted through the 
determination of: a decreased in the level of antioxidants, and an increase in the by-products 
of free radical reactions. The increase of BOOH-CL and TBARS are indicative that -
tocopherol is the antioxidant consumed in erythrocytes and suggest that reactive oxygen 
species and lipid peroxidation catalyzed by reduced transition metals may be responsible 
for the onset of oxidative damage and the occurrence of systemic oxidative stress in PD. The 
levels of intracellular (GSH) and plasma antioxidants are reduced in PD patients, suggesting 
that changes in GSH homeostasis and metabolism are early component of the pathological 
process of PD. SOD increases point to the existence of oxidative insult and systemic 
oxidative stress, alongside with the differences indicated by markers representing 
conditions that change in a few days period, through a marker representing the homeostatic 
long term response of the bone marrow in the order of 60–80 days. 
It is also interesting to note the coincidence resulting from the linear ordering of the 
responses in relation with the complexity of the pathologies (Figures 8 and 9), accordingly 
with the simple Sies scale model. The steady-state formation of prooxidants in cells and organs is 
balanced by a similar rate of their consumption by antioxidants that are enzymatic and/or non-
enzymatic. Oxidative stress results from imbalance in this prooxidant/antioxidant equilibrium in 
favor of the prooxidants (Sies, 1991). 
In pathological situations the reactive oxygen species are generated as a consequence of 
lipid peroxidation and may occur with -tocopherol deficiency. In addition to containing 
high concentrations of polyunsaturated fatty acids and transitional metals, red blood cells 
are constantly being subject to various types of oxidative stress. However, red blood cells 
are protected by a variety of antioxidant systems, capable of preventing most of the adverse 
effects under normal conditions. Among the antioxidant systems, in the red cells, -
tocopherol possesses an important and unique role. -tocopherol may protect the red cells 
from oxidative damage via a free radical scavenging mechanism or as a structural 
component of the cell membranes (Repetto, 2008). 
Cellular oxidative stress and peroxidation of membrane lipids play a role in the pathogenesis 
of PD. A condition of systemic oxidative stress, determined in red blood cells by BOOH-CL 
and SOD activity, and in plasma by TBARS and TRAP, was identified in PD patients. 
Accordingly, there is a statistically significant decrease in the measured TRAP, suggesting that 
an enhanced susceptibility of erythrocytes to the oxidative stress correlates with a decrease in 
its antioxidant defenses. These results indicate that peripheral markers, likely reflecting 
neuronal conditions in red blood cells and plasma, BOOH-CL, TRAP, TBARS and SOD 
evaluated by the present procedures, could be a useful complementary measurement when 
assessing the oxidative stress condition in different clinical pathological situations. Oxidative 
stress is one of the risk factors, which can initiate and/or promote neurodegeneration in PD, 
and correlates with the severity of the disease. The concept that free radicals, lipid 
peroxidation and oxidative stress were involved in the neuronal abnormalities of PD was 
simultaneous with the recognition of complex I dysfunction in PD. The original idea of 
oxidative stress has been extended to oxidative and nitrative stress for the protein damage and 
loss of dopaminergic neurons in Parkinson’s disease (Navarro et al., 2009). 
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Parkinson's disease (PD) results primarily from the death of dopaminergic neurons in the substantia nigra.
Current PD medications treat symptoms; none halt or retard dopaminergic neuron degeneration. The main
obstacle to developing neuroprotective therapies is a limited understanding of the key molecular mechanisms
that provoke neurodegeneration. The discovery of PD genes has led to the hypothesis that misfolding of
proteins and dysfunction of the ubiquitin-proteasome pathway are pivotal to PD pathogenesis. Previously
implicated culprits in PD neurodegeneration, mitochondrial dysfunction, and oxidative stress may also act in
part by causing the accumulation of misfolded proteins, in addition to producing other deleterious events in
dopaminergic neurons. Neurotoxin-based models have been important in elucidating the molecular cascade of
cell death in dopaminergic neurons. PD models based on the manipulation of PD genes should prove valuable
in elucidating important aspects of the disease, such as selective vulnerability of substantia nigra dopaminergic
neurons to the degenerative process.
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